Lightnews — Scholar-powered news

Edgar V. Lerma 🇵🇭

@edgarvlermamd.bsky.social

1.5K followers 47 following 460 posts

Chicago Sports Fan... Nephrologist by day. My tweets are not medical advice. The views expressed here are my own and not those of my employer

Posts Media Videos Starter Packs

Pinned

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · Dec 4

Renal Physiology for the Clinician Series
#Nephpearls

👉 journals.lww.com/cjasn/pages/...

2 19 53

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 1h

Trying to catch up with #IgAN trials⁉️

Check out “IgAN: An Overview of the Clinical Trials” ca. 2025 from @kidneymed.bsky.social
#Nephpearls #RKDSummit #NephSky

👉 pubmed.ncbi.nlm.nih.gov/41050133/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 1h

Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy (IgAN) in Adults
#RKDSummit #Nephpearls #NephSky

👉🏼 www.otsuka.co.jp/en/company/n...

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 1h

APRIL is key 🔑 in the development of Antibody-secreting B lymphocytes ca. 2018 from @JASN_News
#IgAN #Nephpearls #RKDSummit #NephSky

👉 pubmed.ncbi.nlm.nih.gov/29326157/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 1h

Pathogenesis of #IgAN and emerging targets 🎯 ca. 2025
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/40796290/

1 1

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 2h

Impact of Using Risk-Based Stratification on Referral of Patients With CKD From Primary Care to Specialist Care in the United Kingdom ca. 2021 from @kireports.bsky.social
#RKDSummit #Nephpearls #NephSky

#VisualAbstract by @hellokidneymd.bsky.social

👉🏼 pubmed.ncbi.nlm.nih.gov/34386668/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 2h

Treatment targets 🎯 in IgA Nephropathy #IgAN and the positioning of drugs ca. 2025 from @kdigo.org
#Nephpearls #RKDSummit #NephSky

📌 Proteinuria >/= 0.5 g/day (or equivalent) ~ at risk of progressive loss of kidney function

👉🏼 kdigo.org/guidelines/i...

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 2h

A stylized representation of the unmet need in a typical adult patient with #IgAN
#RKDSummit #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/39211339/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 3h

DAPA-CKD: SGLT2 inhibitors (SGLT2i) in IgA Nephropathy and FSGS
#RKDSummit #Nephpearls #NephSky

🔬 IgA Nephropathy
pubmed.ncbi.nlm.nih.gov/33878338/
🔬 FSGS
pubmed.ncbi.nlm.nih.gov/34850160/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 4h

Actionable genes in CKD ca. 2024 from @kdigo.org
#RKDSummit #Nephpearls #NephSky

👉 kdigo.org/guidelines/c...

1 1

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 4h

Genetics 🧬 of FSGS

#VisualAbstract sightings from @kidneyboy.bsky.social @rheaultm.bsky.social @asnpublications.bsky.social

#RKDSummit #Nephpearls

👉🏼 pubmed.ncbi.nlm.nih.gov/30647093/
👉🏼 pubmed.ncbi.nlm.nih.gov/35474271/
👉🏼 pubmed.ncbi.nlm.nih.gov/39190490/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 5h

Spectrum of podocytopathies: Interaction between genetics 🧬 and environment
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/17410103/

1 2

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 6h

Clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome (NS) ca. 2023
#RKDSummit #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/36269406/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 6h

Potential of antinephrin autoantibody measurement for a noninvasive diagnosis of antinephrin-associated podocytopathy ca. 2025 from @kireports.bsky.social
#RKDSummit #Nephpearls

#VisualAbstract by @brianrifkin.bsky.social

👉🏼 pubmed.ncbi.nlm.nih.gov/40814620/

1 2

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 6h

Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria ca. 2025 from @asnpublications.bsky.social
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/40244693/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 17h

Which patients should be on SGLT2 inhibitors (SGLT2i) ⁉️

✅ Check out the SGLT2i Cold 🥶 Map from @theisn.org
#RKDSummit #Nephpearls #NephSky

👉🏼 www.theisn.org/initiatives/...

1 4

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 17h

Interrelation of mechanistic drivers in early through advanced stages of kidney damage and disease progression in diabetes ca. 2022
#RKDSummit #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/35661785/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 18h

High unmet treatment needs in patients w/ CKD & type 2 diabetes (T2D): RWE from a US claims database ca. 2023
#RKDSummit #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/35389468/

📌 Low initiation rates of SOC (ACEi/ ARB) overall & SGLT2i

📌 There were high discontinuation rates for all treatments

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 18h

Theoretical framework for the implementation of GDMT in Type 2 Diabetes (T2D) and CKD ca. 2024
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/38620082/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 18h

Barriers to appropriate medication prescribing and use in CKD ca. 2024
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/39815796/

1 3

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 18h

Stages of cardiovascular-kidney-metabolic (CKM) syndrome
#RKDSummit #Nephpearls #Cardiorenal #NephSky

👉 pubmed.ncbi.nlm.nih.gov/37807924/

1 1

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 19h

Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Patients with IgA Nephropathy #IgAN in a Real-World Database ca. 2024 from @asnpublications.bsky.social
#RKDSummit #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/38323871/

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 1d

Building a Unified Future: The @asnkidney.bsky.social @asnpublications.bsky.social Journal Portfolio 2 Years In from the October 2025 issue of Kidney News
#NephSky

www.kidneynews.org/view/journal...

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 1d

I just donated to the @nephjc.bsky.social Fall 🍂 Drive

Looking forward to learning more #Nephpearls

#NephSky

👉 www.nephjc.com

1 3

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 1d

With a bit of bias towards #NephTwitter, I think 2018-2019

👉 ajkdblog.org/2022/04/20/n...

Edgar V. Lerma 🇵🇭 @edgarvlermamd.bsky.social · 2d

Kidney Translation Podcasts 🎙️ from @asnkidney.bsky.social @asnpublications.bsky.social @nephrosparks.bsky.social
#Nephpearls #NephSky

👉🏼 journals.lww.com/asnjournals/...

1 2